Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 12/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.41 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7387221 | 0.78 | FGFR4 (0.44) | — | |
| SCHEMBL7988808 | 0.77 | TUBB1 (0.60) | MTNR1AAKR1C3MTNR1BTUBB1HTR2C | |
| SCHEMBL9922460 | 0.76 | TXNRD1 (0.46) | MTNR1AMTNR1BHTR2CKDM4E | |
| SCHEMBL30297606 | 0.69 | TFPI2 (0.57) | MTNR1AAKR1C3MTNR1BTUBB1HTR2C | |
| SCHEMBL28409121 | 0.69 | MTNR1A (0.55) | MTNR1AMTNR1BTUBB1HTR2CKDM4E | |
| SCHEMBL5569918 | 0.69 | TFPI2 (0.57) | MTNR1AAKR1C3MTNR1BTUBB1HTR2C | |
| SCHEMBL19382614 | 0.69 | CYP1A2 (0.61) | MTNR1AKDM4E | |
| SCHEMBL29083460 | 0.69 | CYP3A4 (0.40) | MTNR1AAKR1C3MTNR1BTUBB1KDM4E | |
| SCHEMBL2118635 | 0.68 | ALDH1A1 (0.55) | KDM4E | |
| SCHEMBL6400993 | 0.68 | MTNR1A (0.55) | MTNR1ATUBB1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112105385-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2020-12-18 | — | — | CN | disclosed |